Feature|Videos|April 10, 2025
Navigating the Biopharma Landscape: Rentschler's Strategic Shift to Biologics
Author(s)Rentschler Biopharma
Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.
Rentschler Biopharma is pivoting to biologics CDMO services to better align with evolving market demand. Watch this video to learn more about:
- Why the company is undergoing this strategic shift.
- Where the biopharma market is heading, especially in the US and Europe.
- How the company's new strategic orientation supports clients globally to navigate the current (geopolitical) market situation.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5